基本信息
浏览量:569
职业迁徙
个人简介
My own research is focused on three critical areas: developing treatments that target specific signaling pathways that contribute to prostate cancer growth, developing non-invasive methods to determine whether these agents are working, and improving the way drugs are evaluated in the clinic.
Targeted therapies, which attack specific cancer cells without harming normal cells, have the potential to treat cancers with fewer side effects than conventional therapies. Critical to the development of this approach, is to determine which treatment is most likely to be benefit an individual patient. Currently, prostate-specific antigen (PSA) is the best routinely available biomarker providing diagnostic and prognostic information about prostate cancer. PSA testing is useful, but does not reliably determine whether or not a treatment is working, nor does not provide definitive guidance in selecting one therapy over another. My colleagues and I are evaluating promising new technologies to capture and characterize circulating tumor cells from a routine blood draw. We are finding that the number of circulating tumor cells in a patient’s blood helps determine a patient’s prognosis and whether or not a treatment is working. Circulating tumor cells are also providing a biological snapshot of an individual patient’s tumor, which may help determine the choice of therapy.
Targeted therapies, which attack specific cancer cells without harming normal cells, have the potential to treat cancers with fewer side effects than conventional therapies. Critical to the development of this approach, is to determine which treatment is most likely to be benefit an individual patient. Currently, prostate-specific antigen (PSA) is the best routinely available biomarker providing diagnostic and prognostic information about prostate cancer. PSA testing is useful, but does not reliably determine whether or not a treatment is working, nor does not provide definitive guidance in selecting one therapy over another. My colleagues and I are evaluating promising new technologies to capture and characterize circulating tumor cells from a routine blood draw. We are finding that the number of circulating tumor cells in a patient’s blood helps determine a patient’s prognosis and whether or not a treatment is working. Circulating tumor cells are also providing a biological snapshot of an individual patient’s tumor, which may help determine the choice of therapy.
研究兴趣
论文共 899 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)
引用0浏览0引用
0
0
Daniel Vargas P de Almeida,Justine M Anderson,Daniel C Danila,Michael J Morris,Susan F Slovin,Wassim Abida,Erica D Cohn,Raymond E Baser,Howard I Scher,Karen A Autio
Journal of Immunotherapy and Precision Oncologyno. 4 (2023): 162-169
Ethan Barnett,Santosh Gupta,Tatiana Erazo, Ernest Lam Emily Carbone,Michelle Zanone, Lucy Nystrom,Ria N. Gajar, Rick Wenstrup,Howard I. Scher
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)
引用0浏览0引用
0
0
Emily A. Carbone, Ethan S. Barnett,Niamh M. Keegan, Samantha E. Vasselman, Barbara Nweji,Ria N. Gajar,Karen A. Autio,Wassim Abida,Howard I. Scher,Konrad H. Stopsack
引用0浏览0引用
0
0
Journal of Clinical Oncologyno. 6_suppl (2023): 251-251
引用0浏览0引用
0
0
crossref(2023)
Grant Buchanan,Carmela Ricciardelli,Jonathan M. Harris, Jennifer Prescott, Zoe Chiao-Li Yu,Li Jia,Lisa M. Butler, Villis R. Marshall,Howard I. Scher, William L. Gerald,Gerhard A. Coetzee,Wayne D. Tilley
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn